How Biotech Startups Use Digital Twins for Drug Development

Episode 42 of Biotech Business with Fexingo explores how biotech startups are using digital twins—virtual replicas of biological systems, organs, and entire clinical trials—to accelerate drug development and reduce costs. Lucas and Luna dive into the case of Insilico Medicine, which used a digital twin of a patient population to simulate a Phase 2 trial for a novel fibrosis drug, cutting pre-clinical time by 40% and saving an estimated $8 million. They also discuss how startups like Unlearn AI and Novadiscovery are running virtual control arms, replacing placebo groups with synthetic data to shrink trial sizes. The episode touches on the FDA's evolving stance on in silico evidence and the hurdles of validation. By the end, listeners will understand how digital twins could shave years off the typical 10-15 year drug development timeline and why big pharma is already investing billions in simulation platforms. #DigitalTwins #DrugDevelopment #InsilicoMedicine #UnlearnAI #Novadiscovery #FDA #InSilicoTrials #VirtualControlArms #BiotechStartups #Simulation #PrecisionMedicine #ClinicalTrials #ArtificialIntelligence #DrugDiscovery #Business #Technology #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo